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Abstract
Background: Hypertriglyceridemia (HTG) is a common complex metabolic trait that results of the accumulation of
relatively common genetic variants in combination with other modifier genes and environmental factors resulting
in increased plasma triglyceride (TG) levels. The majority of severe primary hypertriglyceridemias is diagnosed in
adulthood and their molecular bases have not been fully defined yet. The prevalence of HTG is highly variable
among populations, possibly caused by differences in environmental factors and genetic background. However, the
prevalence of very high TG and the frequency of rare mutations causing HTG in a whole non-selected population
have not been previously studied.
Methods: The total of 23,310 subjects over 18 years from a primary care-district in a middle-class area of Zaragoza
(Spain) with TG >500 mg/dL were selected to establish HTG prevalence. Those affected of primary HTG were
considered for further genetic analisys. The promoters, coding regions and exon-intron boundaries of LPL, LMF1,
APOC2, APOA5, APOE and GPIHBP1 genes were sequenced. The frequency of rare variants identified was studied in
90 controls.
Results: One hundred ninety-four subjects (1.04 %) had HTG and 90 subjects (46.4 %) met the inclusion criteria for
primary HTG. In this subgroup, nine patients (12.3 %) were carriers of 7 rare variants in LPL, LMF1, APOA5, GPIHBP1 or
APOE genes. Three of these mutations are described for the first time in this work. The presence of a rare
pathogenic mutation did not confer a differential phenotype or a higher family history of HTG.
Conclusion: The prevalence of rare mutations in candidate genes in subjects with primary HTG is low. The low
frequency of rare mutations, the absence of a more severe phenotype or the dominant transmission of the HTG
would not suggest the use of genetic analysis in the clinical practice in this population.
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Background
Hypertriglyceridemia (HTG) is a common complex meta-
bolic trait resulting in increased plasma triglyceride (TG)
levels, atherosclerosis risk, metabolic syndrome and in se-
vere cases, high risk of acute pancreatitis [1]. HTG has
been generally classified as primary, when a familial or
inherited basis is suspected, whereas secondary HTG re-
fers to cases in which coexist one or more identifiable
conditions favouring HTG, including metabolic syndrome,
type 2 diabetes, excess alcohol consumption, obesity, renal
disease or certain drugs [2]. Selected primary very high
HTG cases from lipid clinics, usually defined with TG >
500 mg/dL, are the result of the accumulation of relatively
common genetic variants, with small to modest effect on
TG, and/or the presence of rare mutations with large ef-
fect on TG in combination with other modifier genes and
environmental factors [3, 4]. Hence, genetic studies in
most HTG are predicted to add little information in their
clinical management. In contrast, primary severe HTG
with plasma triglyceride concentrations > 1000 mg/dL [5]
concentrate rare mutations with major effects in genes in-
volved in triglyceride-rich lipoprotein metabolism, includ-
ing LPL, APOC2, APOA5, LMF1, APOE and GPIHBP1
genes [6–9]. Homozygosity or compound heterozygosity
for severe mutations in these genes comprise the most se-
vere cases of HTG, with TG well over 1,000 mg/dL and
recurrent episodes of pancreatitis since childhood in many
occasions. However, these autosomal recessive defects are
extremely rare, approximately 1:1,000,000, and most cases
of very high HTG do not fulfil these criteria [10].
The prevalence of very high HTG is highly variable
among populations, possibly caused by differences in en-
vironmental factors like diabetes prevalence or alcohol
consumption, genetic background, and cohort selection.
However, the prevalence of very high TG and the fre-
quency of rare mutations causing HTG in a whole non-
selected population have not been previously studied.
This information could be very useful to establish the
role of genetic testing and familial cascade screening for
primary HTG.
Methods
Study subjects
The Spanish public health system distributes the popula-
tion in different health districts, approximately 20,000–
30,000 patients per district. Each health district includes
100 % of citizens living in that district. They share a
single primary care facility, a single laboratory with
computerized data since 2005, and a centralized registry
of drugs. For this study, we selected all subjects of a pri-
mary care district (Centro Salud Almozara) in a middle
class area of Zaragoza city in northern Spain. This facility
is responsible of the primary health care of 23,310 sub-
jects, which includes voluntary periodic examinations with
fasting blood test every 5 years. All adult subjects
(≥18 years of age) of Centro Salud Almozara were in-
cluded in the study to establish the frequency of HTG
in general population.
HTG definition and HTG subjects selection
Very high HTG was defined with fasting TG > 500 mg/dL
as proposed by Adult Treatment Panel III guideline rec-
ommendations [5]. HTG subject was defined as the pres-
ence in the last 10 years of very high TG, and at least two
other measurements with TG >200 mg/dL. Subjects under
treatment with drugs to decrease triglycerides (fibrates,
omega-3 fatty acids or niacin) were considered as HTG in
presence of a single TG value > 500 mg/dL. Secondary
very high HTG was an exclusion criterion, and was con-
sidered in presence of uncontrolled diabetes (Hb1Ac
>7.5 %) , obesity (body mass index >30 Kg/m2), alcohol
abuse (>30 g/day for men and >20 g/day for women),
renal disease (glomerular filtration rate <30 mL/min), liver
disease (ALT >3 times upper normal limit) except non-
alcoholic fatty liver, hypothyroidism (TSH >6 μUI/mL),
pregnancy, hemochromatosis, autoimmune diseases, and
concomitant use of estrogens (except contraceptive pills),
any dose of oral corticosteroids or protease inhibitors.
Normolipemic subjects
The normolipemic group consisted of healthy, unrelated
men and women volunteers from the same facility,
matched by age with the HTG group. Exclusion criteria
for control subjects were TG >100 mg/dL, diabetes,
current or past history of lipid-lowering drug consump-
tion and APOE genotype other than ε3/ε3.
All selected subjects, cases and controls, signed in-
formed consent to a protocol previously approved by
our local ethical committee (Comité Ético de Investiga-
ción Clínica de Aragón, Zaragoza, Spain).
Clinical and laboratory determinations
All participants were assessed for personal and familial
history of cardiovascular disease, history of pancreatitis,
medication use, cardiovascular risk factors and anthropo-
metric measurements. Dietary intake in cases and controls
was determined by interview with one single registered
dietician. In this interview, a Spanish validated 137-item
food frequency questionnaire (FFQ) was used [11].
EDTA plasma and serum samples were collected after
10–12 hours of fasting. Cholesterol and TG levels were
determined by standard enzymatic methods. HDL
cholesterol was measured directly by an enzymatic re-
action using cholesterol oxidase (UniCel DxC 800;
Beckman Coulter, Inc., Brea, CA, USA). Apo A1, apo
B, lipoprotein(a) and C-reactive protein were deter-
mined by IMMAGE kinetic nephelometry (Beckman-
Coulter, Inc.).
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Genetic analysis
DNA was extracted by standard methods. Promoters,
coding regions and intron-exon boundaries of LPL
(NM_000237), LMF1 (NM_022773), APOA5 (NM_052968),
APOC2 (NM_000483.4) and GPIHBP1 (NM_178172)
were amplified by PCR and purified by ExoSap-IT
(USB) using primers shown in (Additional file 1: Table S1).
Amplified fragments were sequenced by Sanger method
using the BigDye 3.1 sequencing kit (Applied Biosystems)
in an automated ABI 3500xL sequencer (Applied Biosys-
tems). DNA sequences were analyzed using VariantRepor-
ter™ software (Applied Biosystems). APOE genotype was
determined as previously described [12].
Rare and common variants were defined by frequen-
cies <1 % and >1 % respectively of that obtained from
the 1000 Genomes project [13]. Variants that were not
previously described and absent in our control popula-
tion were considered as rare. Rare and common variants
were considered pathogenic if previously associated with
HTG or considered pathogenic by the evaluation with
predictive software in a bioinformatic analysis.
To evaluate the pathogenicity of newly identified gen-
etic variants, we used PolyPhen-2 [14] and Mutation
Taster [15]. The effect of variants in potential splicing
sites was predicted with NetGene2 [16] and NNSplice
[17]. We refer to non-synonymous variants as sequence
variations causing amino acid substitutions (missense
variants) or introducing of a premature stop codon
(nonsense variants). Intronic variants were considered
when they were located in intron-exon boundaries.
In order to compare the frequency of identified vari-
ants with that of the general population we have com-
piled the allele frequencies of the identified variants
from the 1000 Genomes Project [13].
Statistical analysis
Analyses were performed using SPSS version 20.0 (IBM).
The nominal level for significance was p < 0.05. Normal
distribution of variables was checked by Kolmogorov–
Smirnov test. Quantitative variables with normal distri-
bution were expressed as mean ± standard deviation and
were analyzed by T-Student test. Variables with a skewed
distribution were expressed as median and interquartile
range and were analyzed by Mann–Whitney U test.
Qualitative variables were expressed as percentage and
were analyzed by Chi-square test.
Results
From the total selected population of 23310 subjects,
18804 subjects were aged 18–80 years, 194 (1.04 %) of
them presented very high HTG in the last 10 years, and
90 subjects (46.4 %) met the inclusion criteria for pri-
mary HTG. The selection of study subjects group was
carried out as indicated in the flow chart of Fig. 1.
Finally, 73 patients with primary very high HTG were
studied by sequencing the LPL, LMF1, APOA5, APOC2,
GPIHBP1 and APOE genes.
Anthropometric and clinical characteristics of the
patients with primary HTG and control subjects are
shown in Table 1. In the primary HTG group, there was a
clear predominance of males (79.5 %) with a mean
age of 56.4 years. Cardiovascular disease, diabetes and
hypertension were more frequent among cases than
in controls (Table 1).
Sequencing analysis of LPL, LMF1, APOA5, GPIHBP,
APOC2 and APOE genes revealed that nine patients out
of 73 (12.3 %), were carriers of 7 rare variants: c.1018 +
1G >A in LPL, p.(Leu69Leu) and p.(Pro562Arg) in LMF1,
p.(Leu173Pro) and p.(Gln97*) in APOA5, p.(Arg76Cys)
in GPIHBP1 and p.(Arg154Ser) in APOE . Three of them
were described for the first time in this work: c.1018 +
1G >A in LPL, p.(Leu173Pro) in APOA5, and p.(Arg76Cys)
in GPIHBP1. Only the variant p.(Pro562Arg) in LMF1 was
also present in controls (Table 2).
For all the identified variants, the in silico analysis with
MutationTaster and PolyPhen-2 was performed to
evaluate the pathogenicity. The following variants were pre-
dicted as potentially harmful: c.-281G >C, c.1018 + 1 G >
A, p.(Asp36Asn) and p.(Asn318Ser) in LPL; p.(Ser19Trp),
p.(Gln97*), and p.(Leu173Pro) in APOA5, p.(Ser144Phe)
and p.(Arg76Cys) in GPIHBP1 and p.(Arg364Gln),
p.(Pro562Arg), p.(Leu69Leu) in LMF1. This last variant in
LMF1, although silent variant, was predicted as potentially
harmful, since splicing score was increased (score wild
type: 0.43 versus score mutant: 0.48).
Table 3 shows identified variants with allelic frequen-
cies statistically different from those described in the
1000 Genomes project: p.(Asp36Asn) and c.-281T > G in
LPL, and p.(Ser19Trp) and c.-3A > G in APOA5. Other
polymorphisms previously associated with HTG [18, 19]
were also present in our HTG population: p.(Ser474X) in
LPL; and p.(Arg364Gln), p.(Arg354Trp) and p.(Pro562Arg)
in LMF1, but their frequencies were not statistically differ-
ent from those described in the 1000 Genomes project.
The protector polymorphism, p.(Ser474X) in LPL, was
found in our HTG population with lower frequency
(11.1 %) that in the 1000 Genomes project (12.2 %), al-
though this difference did not reach statistical significance.
The clinical characteristics of the 9 patients carrying
the 7 rare variants are shown in Table 4. The anthropo-
metric and clinical data did not significantly differ be-
tween carriers and non-carriers of rare functional
variants, including family history of HTG (Table 5).
Discussion
The prevalence of very high HTG in subjects aged 18 to
80 from the general population was 1.04 % in our study.
To our knowledge, there are not similar studies
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including all (>99 %) subjects of a large community
followed for 10 years. Due to the large variability of TG
levels, we have considered those subjects with at least
two separated determinations to confirm the high TG
levels. The specific design of our study allows us to be
confident about the consistency of our results. The char-
acteristic of our national health system and the highly
stable population, without significant immigration or
emigration processes in the area of study in the last
10 years, reinforce our calculations. Furthermore, our re-
sults are concordant with other transversal studies such
as the NHANES in a representative USA population,
with an overall prevalence of 1.1 % of subjects with TG >
500 mg/dL [18]. Moreover, the frequency of HTG was
1.12 %, when defined as TG >400 mg/dL, in stratified
sampling with a transversal design in the Spanish popu-
lation [19]. This prevalence seems to be higher in other
populations, especially Mexican American middle-aged
men, probably due to differences in genetic background,
diet, and prevalence of obesity [18].
Primary HTG is defined as a lipoprotein metabolism
disturbance caused by alteration of genes and proteins
that regulate lipid metabolism. Of the 194 subjects who
had TG > 500 mg/dL, 104 met criteria for secondary
HTG. This means that less than half of the HTG sub-
jects (43.6 %) considered to have a predominantly
Fig. 1 Flow chart of the population selected for this study
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genetic cause in our population, and is consistent with
previous reports [20]. In our population, the major risk
factor for secondary HTG was obesity (41.1 %). This per-
centage is similar to that found in the American popula-
tion, in which 42.9 % of subjects with TG 200 mg/dL
were classified as obese [18].
According to our results, the prevalence of HTG, both
primary and secondary, was considerably lower among
women than in men. In our HTG population, there was
a clear predominance of males (79.5 %), as in the
NHANES study, in which the 75.3 % of HTG were
men [21], and also largely corroborated in other studies
[22, 23]. The mechanism of this difference is not fully
established. No locus related to triglycerides in sexual
chromosomes has been found in GWAS, so the differ-
ences are probably due to different interaction of common
gene variations with certain environmental factors.
For example, a significantly greater efficiency of skeletal
muscle to the postprandial clearance of both total and
meal- derived triglycerides in women relative to men has
been described and could explain a different impact of
obesity on TG between genders [24].
Another objective our study was to determine the fre-
quency of pathogenic mutations causing high TG levels
in LPL, LMF1, APOA5, GPIHBP1, APOC2 and APOE
genes in subjects with primary HTG. The analysis of the
pathogenicity of the identified variants revealed that 9
out of 73 subjects were carriers of 7 disease causing vari-
ants in the candidate genes. Therefore, 12.3 % of our
population had a disease causing variant. This frequency
is similar to that observed by Wang et al., who studied
110 subjects with severe HTG and analyzing rare vari-
ants in LPL, APOA5 and APOC2 genes obtained a muta-
tion frequency of 10.9 % [22].
Of the 7 variants disease causing, only one of them,
p.(Pro562Arg) in LMF1, is present in controls. This mu-
tation has been associated with HTG in previous studies
[4–25] and its frequency in the general population of the
1000 Genomes project is lower than 1 % [13]. However,
it would be necessary to perform further functional ana-
lysis to analyze the potencial effect of this variant.
The silent variant p.(Leu69Leu) in LMF1 was found to
be pathogenic according to bioinformatic analysis. It
does not generate an amino acid change, but it could
generate a change in the physiological splicing according
to bioinformatic analysis. Silent variants have been
described as pathogenic by previous studies, showing
that these variants can influence binding of regulatory
factors on DNA, mRNA secondary structure and stability,
ribosome traffic on mRNA and its interactions with
Table 1 Clinical and biochemical characteristics of primary HTG
and control groupsa
Primary HTG Control p
N = 73 N = 90
Age, years 56.4 ± 12.0 53.5 ± 16.2 0.210
Males, n (%) 58 (79.4) 45 (50.0) 0.000
Body mass index, kg/m2 27.6 ± 2.35 26.6 ± 3.25 0.044
Total cholesterol, mg/dL 264 ± 48.0 196 ± 34.1 0.000
Triglycerides, mg/dL 654 (550–810) 63.0 (49.7–74.0) 0.000
HDL cholesterol, mg/dL 40.1 ± 10.5 55.2 ± 12.6 0.000
Glucose, mg/dL 100 ± 16.1 91.3 ± 12.7 0.000
Hb1Ac (%) 5.6 (5.3–6.15) 5.3 (5.1–5.5) 0.000
Diabetes, n (%) 18 (24.7) 2 (2.3) 0.000
Hypertension, n (%) 31 (42.5) 13 (14.4) 0.000
Cardiovascular disease, n (%) 11 (15.1) 3 (3.3) 0.005
APOE genotype (%) 0.000
ε2- ε2 0 0
ε2- ε3 19.7 0
ε3- ε3 57.7 100
ε3- ε4 16.9 0
ε4- ε4 1.4 0
ε4- ε2 4.2 0
Quantitative variables are expressed as mean ± standard deviation, except for
variables not following normal distribution, expressed as median (interquartile
range). Qualitative variables are expressed as %. The p value was calculated by
Student’s t test, Mann–Whitney U and Chi - square as appropriate.
aLipid values refer to the most recent values without lipid-lowering treatment
Table 2 Rare gene variants identified in the studied HTG population
Gene Localization Variant Predicted aminoacid change HTG group
N (%)
Bioinformatic Analysis Control group
LPL Intron 6 c.1018 + 1G > A 2 (2.74 %) Damage 0
LMF1 Exon 2 c.205 p.(Leu69Leu) 1 (1.37 %) Damage 0
Exon 11 c.1685C > G p.(Pro562Arg) 1 (1.37 %) Damage 2 (2.2 %)
APOA5 Exon 4 c.289C > T p.(Gln97*) 1 (1.37 %) Damage 0
c.518T > C p.(Leu173Pro) 1 (1.37 %) Damage 0
GPIHBP1 Exon 2 c.226C > T p.(Arg76Cys) 1 (1.37 %) Damage 0
APOE Exon 4 c.460C > A p.(Arg154Ser) 2 (2.74 %) Damage 0
Prediction of deleterious effects was performed using SIFT (http://sift.jcvi.org/), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and
MutationTaster (http://www.mutationtaster.org)
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specific ligands (as in riboswitches), including other
RNAs and proteins [26]. It would be necessary to
perform a functional analysis to study the potential
effect of this variant.
Among the mutations identified in our population,
three of them have been described for the first time in
this work: p.(Leu173Pro), located in APOA5 exon 4,
that generates an amino acid change predicted as harm-
ful by bioinformatic analysis; c.1018 + 1 G > A, that
causes a change in splicing site in LPL intron 6, and
p.(Arg76Cys), located in GPIHBP1 exon 2 and produ-
cing an amino acid change also predicted as harmful by
in silico analysis. Among our cases, none homozygous
or compound heterozygous subject was found. Taking
into account that these mutations were not found in
the normolipemic population, we considered that these
variants are playing an important role in the HTG
phenotype of carrier subjects, and that severe HTG
could be considered a co-dominant disease with vari-
able penetrance. There is a large heterogeneity in the
variants identified in our study. Only the changes
c.1018 + 1G > A in LPL and p.(Arg154Ser) in APOE
were present in two unrelated affected subjects. This is
in agreement with observations in other genetic dis-
eases in our population and could be due to the ab-
sence of a common genetic background in Spain [27].
Table 3 Comparison of allele frequencies of variants in our HTG population and 1000 Genomes project
Gene Nucleotide change Predicted aminoacid
change
Frequency in
HTG population
Frequency in the
population 1000 Genomes
p Bioinformatic Analysis
LPL c.106G > A p.(Asp36Asn) 0.055 0.013 0.001 Benign
c.−281T > G 0.062 0.013 <0.001 Damage
LMF1 c.205C > T p. (Leu69Leu) 0.007 0.0001 0.017 Damage
c.288 + 298C > T 0.007 0.394 <0.001 Benign
APOA5 C.−3 A > G 0.185 0.080 <0.001 Benign
c.56C > T p.(Ser19Trp) 0.185 0.057 <0.001 Damage
c.132C > A p.(Ile44Ile) 0.178 0.056 <0.001 Benign
c.162-43A > G 0.134 0.080 0.040 Benign
GPIHBP1 c.−509 G > A 0.164 0.442 <0.001 Unknown
c. −208 G > C 0.240 0.443 <0.001 Unknown
c.138G > T p.(Val46Val) 0.281 0.443 0.0003 Benign
c.295 + 19G > A 0.007 0.000 0.0226 Benign
c.295 + 28G > A 0.007 0.000 0.0226 Benign
APOC2 c.−116T > A 0.50 0.376 0.004 Benign
c.−89C > G 0.027 0.009 0.048 Benign
c.56–30G > A 0.007 0.000 0.008 Benign
c.216–81T > C 0.344 0.491 0.007 Benign
All variants are described in accordance with the latest recommendations of HGVS (http://www.hgvs.org/mutnomen). The p value was calculated by χ2 test
Prediction of deleterious effects was performed using SIFT (http://sift.jcvi.org/ ), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and
MutationTaster (http://www.mutationtaster.org)
Table 4 Clinical characteristics of patients carrying rare variants in LPL, LMF1, APOA5, APOE and GPIHBP1 genes
Gene Nucleotide change Predicted aminoacid change Age (years) Sex BMI (kg/m2) TC, mg/dL TG mg/dL APOE Genotype
LPL c.1018 + 1G > A 74 F 26.3 247 505 ε2/ε3
59 M 29.7 374 1736 ε3/ε4
LMF1 c.205C > T p. (Leu69Leu) 65 M 24.2 257 654 ε3/ε4
c.1685C > G p.(Pro562Arg) 28 M 26.85 286 932 ε2/ε3
APOE c.460C > A p.(Arg154Ser) 47 M 24.45 354 572 ε3/ε3
64 M 29.1 287 586 ε3/ε3
APOA5 c.289C > T p.(Gln97*) 53 M 23.9 252 1215 ε2/ε3
c.518T > C p.(Leu173Pro) 43 M 28.9 269 1410 ε3/ε4
GPIHBP1 c.226C > T p.(Arg76Cys) 57 M 29.8 251 781 ε2/ε3
BMI Body Mass Index, TC Total Cholesterol, TG Triglycerides, F female, M male
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One important issue in our results is the lack of clinical
differences between cases with and without mutation.
Therefore, the presence of a rare pathogenic mutation did
not confer a differential phenotype or risk with respect to
those subjects without mutations, neither useful informa-
tion in the management of these subjects.
Conclusions
In conclusion, we are far from knowing the full genetic
basis of severe HTG, but the presence of rare mutations
in candidate genes do not appear to be responsible in
most cases. The low frequency of rare mutations in can-
didate genes and the absence of a more severe pheno-
type and family history of dominant transmission in
those with rare mutations would not suggest the use of
genetic analysis in clinical practice in this type of HTG.
It would be possible that the study of known genes with
minor effects on triglycerides like GPD1, GCKR, CREB3L3,
MET or INSR the discovery of new HTG genes, or the
use of new large scale tecniques may change this approach
in the future [28, 29].
Additional files
Additional file 1: Tables S1. Primers used for sequencing of candidate
genes. (DOCX 109 kb)
Abbreviations
FFQ: food frequency questionnaire; HTG: hypertriglyceridemia;
TG: triglyceride.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
ILM performed the experiments and contributed to the writing of the
manuscript. FC and IDC contributed substantially to the conception and
design; all authors participated in acquisition, analysis and interpretation of
the data, in the drafting of the article or critical revision and in final approval
of the version to be published.
Acknowledgements
Grants from the Spanish Ministry of Health FIS PI13/02507, FIS PI15/01983,
RD12/0042/0055 and Cuenca Villoro Fundation supported this work.
Author details
1Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón
(IIS Aragón), Avenida Isabel La Católica 1-3, 50009 Zaragoza, Spain.
2Universidad de Zaragoza, Departamento de Bioquímica, Biología Molecular
y Celular, 50009 Zaragoza, Spain.
Received: 17 February 2016 Accepted: 18 April 2016
References
1. Wilson PW, Grundy SM. The metabolic syndrome: a practical guide to
origins and treatment: Part II. Circulation. 2003;108:1537–40.
2. Hegele RA, Pollex RL. Hypertriglyceridemia: phenomics and genomics. Moll
Cell Biochem. 2009;236:35–43.
3. De Castro-Orós I, Cenarro A, Tejedor MT, Baila-Rueda L, Mateo-Gallego R,
Lamiquiz- Moneo I, et al. Common genetic variants contribute to primary
hypertriglyceridemia without differences between familial combined
hyperlipidemia and isolated hypertriglyceridemia. Circ Cardiovasc Genet.
2014;7:814–21.
4. Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, et al.
Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe
hypertriglyceridemia. J Intern Med. 2012;272:185–96.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation. 2002;106:3143–421.
6. Gary FL, Changting X, Hegele RA. Hypertriglyceridemia in the Genomic Era:
A New Paradigm. Endocr Rev. 2015;36:131–47.
7. Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride
metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol.
2006;17:122–7.
8. Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger
CR, et al. Mutations in LMF1 cause combined lipase deficiency and severe
hypertriglyceridemia. Nature Genet. 2007;39:1483–7.
9. Davies BS, Beigneux AP, Barnes RH, Tu Y, Gin P, Weinstein MM, et al.
GPIHBP1 is reponsible for the entry of lipoprotein lipase into capillares. Cell
Metab. 2010;12:42–52.
10. Borge GN, Varbo A. Lipids and cardiovascular disease 3. Lancet. 2014;384:626–35.
11. De la Fuente-Arrillaga C, Ruiz MV, Bes-Rastrollo M, Sampson L, Martinez-
González MA. Reproducibility of an FFQ validated in Spain. Public Health
Nutr. 2010;28:1–9.
12. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-
stage PCR. Lancet. 1999;337:1158–9.
13. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD,
DePristo MA, Durbin RM. An integrated map of genetic variation from
1,092 human genomes. Nature. 2012;491:56–65.
14. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
et al. A method and server for predicting damaging missense mutations.
Nat Methods. 2010;7:248–9.
Table 5 Clinical characteristics of HTG subjects according to
presence/absence of rare variants
Clinical characteristics Mutation
carriers (n = 9)
Non-mutation
carriers (n = 64)
p
Age (years) 59.8 ± 11 55,9 ± 12,2 0.017
Male n, (%) 8 (88.9 %) 50 (78.1 %) 0.058
BMI (kg/m2) 26.3 (24.0–29.4) 28,0 (25.9–29.7) 0.276
APOE genotype (%) 0.336
ε2-ε3 33.3 17.2
ε3-ε3 33.3 62.5
ε3-ε4 33.3 14.1
ε4-ε4 0 1.6
ε4-ε2 0 4.7
Triglycerides, mg/dL 583 (529–1095) 669 (580–848) 0.416
Total cholesterol, mg/dL 281 ± 48.9 262 ± 48.1 0.743
HDL cholesterol, mg/dL 40.4 ± 9.67 40.1 ± 10.6 0.881
Diabetes, % 11.1 26.6 0.314
Hypertension, % 22.2 43.7 0.219
Cardiovascular disease, % 22.2 14 0.522
Familial history (%) 22.2 12.5 0.421
Quantitative variables are expressed as mean ± standard deviation, except
for variables without normal distribution (median, interquartile range).
The qualitative variables are expressed as %. BMI: body mass index
P value was calculated by Student’s t test, Mann - Whitney U and Chi – square,
as appropriate
Lamiquiz-Moneo et al. Lipids in Health and Disease  (2016) 15:82 Page 7 of 8
15. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster
evaluates disease-causing potential of sequence alterations. Nat Methods.
2010;7:575–6.
16. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and
acceptor sites from the DNA sequence. J Mol Biol. 1991;220:49–65.
17. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection
inGenie. J Comput Biol. 1997;4:311–23.
18. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.
Triglycerides and cardiovascular disease: a scientific statement from the
American Heart Association. Circulation. 2011;123:2292–333.
19. Guallar-Castillón P, Pérez RF, López García E, León-Muñoz LM, Aguilera MT,
Graciani A, et al. Magnitude and management of metabolic syndrome in
Spain in 2008–2010: the ENRICA study. Rev Esp Cardiol. 2014;67:367–73.
20. Valdivielso P, Pintó X, Mateo-Gallego R, Masana L, Álvarez-Sala L, Jarauta E,
et al. Clinical features of patients with hypertriglyceridemia referred to lipid
units: registry of hypertrigliceridemia of the Spanish Arteriosclerosis Society.
Med Clin. 2011;136:231–8.
21. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe
(500 to 2,000 mg/dl) hypertriglyceridemia in United States adults.
Am J Cardiol. 2011;107:891–7.
22. Wang J, Cao H, Ban RM, Kennedy BA, Zhu S, Anand S, et al. Resequencing
Genomic DNA of patients with severe Hypertriglyceridemia (MIM 144650).
Arterioscler Thromb Vasc Biol. 2007;27:2450–5.
23. Carrol MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon JD, Wolz M, et al.
Trends in Serum Lipids and liporproteins of adults, 1960–2002. JAMA.
2005;294:1773–81.
24. Horton TJ, Commerford R, Pagliassotti MJ, Bessesen DH. Postprandial leg
uptake of triglyceride is greater in women than in men. Am J Physiol
Endrocrinol Metab. 2002;283:1192–202.
25. Hegele RA, Ban RM, Hsueh N, Kennedy BA, Cao H, Yong Zou G, et al.
A polygenic basis for four classical Fredrickson hyperlipoproteinemia
phenotypes that are characterized by hypertriglyceridemia. Hum Mol
Genet. 2009;21:4189–94.
26. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous
mutations to human disease. Nat Rev Genet. 2011;12:683–91.
27. Cenarro A, Jensen HK, Casao E, Civeira F, González-Bonillo J, Rodríguez-Rey
JC, et al. Identification of recurrent and novel mutations in the LDL receptor
gene in Spanish patients with familial hypercholesterolemia. Hum Mutat.
1998;11:413–8.
28. Willer C, Schmidt E, Sengupta S, Peloso G, Gustafsoon S, Kanoni S, et al.
Discovery and Refinement of Loci Associated with Lipid Levels. Nat Genet.
2013;45:1–24.
29. Wu JW, Yang H, Wang SP, Soni KG, Brunel-Guitton C, Mitchell GA.
Inborn errors of cytoplasmic triglyceride metabolism. J Inherit Metab
Dis. 2015;38:85–98.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lamiquiz-Moneo et al. Lipids in Health and Disease  (2016) 15:82 Page 8 of 8
